Nicolás Colaianni-Alfonso

Mr. Nicolás Colaianni-Alfonso

Unidad Soporte Ventilatorio No Invasivo, Hospital Fernández, Buenos Aires, Argentina
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2021 in Respiratory Care
Verified
Journal Article
Closed access
PDF file
Nicolás Colaianni-AlfonsoNicolás Colaianni-Alfonso
Nicolás Colaianni-Alfonso
GMGuillermo Montiel
Guillermo Montiel
Mauro Ariel Castro SayatMauro Ariel Castro Sayat
Mauro Ariel Castro Sayat
CSCatalina Siroti
Catalina Siroti
MVMaria Laura Vega
Maria Laura Vega
JAJosé Miguel Alonso-Íñigo
José Miguel Alonso-Íñigo
BACKGROUND: The roles of high-flow nasal cannula (HFNC) and CPAP in coronavirus disease 2019 (COVID-19) are controversial. The objective of the study was to evaluate the impact of the application of a noninvasive respiratory support algorithm on clinical outcomes in subjects with COVID-19 and with acute respiratory failure. METHODS: We performed a single-center prospective observational study of subjects with respiratory failure from COVID-19 managed with HFNC and with CPAP plus HFNC (combined therapy). The main outcome was the intubation rate, which defined failure of therapy. We also analyzed the role of the ROX index ([ S pO 2 / F IO 2 ]/breathing frequency) to predict the need for intubation. RESULTS: From June to December 2020, 113 subjects with COVID-19 respiratory failure were admitted to our respiratory intermediate care unit. HFNC was applied in 65 subjects (57.52%) and combined therapy in 48 subjects (42.47%). A total of 83 subjects (73.45%) were successfully treated with noninvasive respiratory support. The intubation rate was 26.54%, and the overall mortality rate was 14.15%. The mortality rate in subjects who were intubated was 55.2%. An ROX index of 6.28 at 12 h predicted noninvasive respiratory support failure, with 97.6% sensitivity and 51.8% specificity. CONCLUSIONS: Data from our cohort managed in a respiratory intermediate care unit showed that combined noninvasive respiratory support was feasible, with favorable outcomes. Further prospective studies are required.

19 December 2024 in Journal of Intensive Medicine
Verified
Journal Article
Open access
Nicolás Colaianni-AlfonsoNicolás Colaianni-Alfonso
Nicolás Colaianni-Alfonso
FHFederico Herrera
Federico Herrera
DFDiego Flores
Diego Flores
Cristian DeanaCristian Deana
Cristian Deana
MVMina Vapireva
Mina Vapireva
Luigi VetrugnoLuigi Vetrugno
Luigi Vetrugno
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death worldwide. During severe exacerbations, COPD patients may develop acute respiratory failure (ARF), often necessitating hospital admission due to impaired gas exchange. In COPD patients, the diaphragm is subjected to an increased workload resulting from airflow limitations and geometric changes in the thorax due to pulmonary hyperinflation. Noninvasive ventilation (NIV) plays a crucial role in managing type II ARF by improving alveolar ventilation, reducing the work of breathing, minimizing the need for endotracheal intubation (ETI), and decreasing both hospital stays and mortality rates. Studies have shown that approximately 64% of patients with acute exacerbation of COPD (AECOPD) may fail NIV, primarily due to worsening respiratory function, interface intolerance, cardiovascular instability, or neurological deterioration. For patients intolerant to NIV, a trial with a high-flow nasal cannula (HFNC) is recommended. Recently, HFNC has gained popularity as a novel respiratory support system and is increasingly used in routine clinical practice for AECOPD patients. It delivers warmed, humidified, and oxygen-enriched air through a nasal cannula at flow rates of up to 60 L/min. This narrative review aims to describe the physiological effects of HFNC in the COPD population and provide an updated overview of HFNC's role in AECOPD patients requiring hospitalization.

11 April 2023 in Respiratory Care
Verified
Journal Article
Closed access
PDF file
Nicolás Colaianni-AlfonsoNicolás Colaianni-Alfonso
Nicolás Colaianni-Alfonso
RMRonan MacLoughlin
Ronan MacLoughlin
AEAriel Espada
Ariel Espada
YSYasmine Saa
Yasmine Saa
MTMariano Techera
Mariano Techera
Mauro Ariel Castro SayatMauro Ariel Castro Sayat
Mauro Ariel Castro Sayat
BACKGROUND: Bronchodilator delivery via a high-flow nasal cannula (HFNC) has generated interest in recent years. The efficacy of in-line vibrating mesh nebulizers with an HFNC during COPD exacerbation is limited. The aim of this study was to evaluate the clinical response of subjects with COPD exacerbation who require bronchodilator therapy (anticholinergic and β-agonist) by using a vibrating mesh nebulizer in line with an HFNC. METHODS: This was a prospective single-center study performed in a respiratory intermediate care unit that enrolled patients with a diagnosis of COPD exacerbation who required noninvasive ventilation on admission. All the subjects underwent noninvasive ventilation breaks with an HFNC. After clinical stability, pulmonary function tests were performed to assess changes in FEV 1 and clinical parameters before and after bronchodilation by using a vibrating mesh nebulizer in line with an HFNC. RESULTS: Forty-six patients with COPD exacerbation were admitted. Five patients who did not use noninvasive ventilation and 10 patients who did not receive bronchodilator treatment with a vibrating mesh nebulizer were excluded. Thirty-one were selected, but 1 subject was secondarily excluded due to loss of data. Finally, 30 subjects were included. The primary outcome was spirometric changes in FEV 1 . The mean ± SD FEV 1 before receiving bronchodilator treatment by using a vibrating mesh nebulizer in line with an HFNC was 0.74 ± 0.10 L, and, after receiving treatment, the mean ± SD FEV 1 changed to 0.88 ± 0.12 L ( P < .001). Similarly, the mean ± SD FVC increased from 1.75 ± 0.54 L to 2.13 ± 0.63 L ( P < .001). Considerable differences were observed in breathing frequency and heart rate after receiving bronchodilator treatment. No relevant changes were observed in the Borg scale or S p O 2 after treatment. The mean clinical stability recorded was 4 d. CONCLUSIONS: In subjects with COPD exacerbation, bronchodilator treatment by using a vibrating mesh nebulizer in line with an HFNC showed a mild but significant improvement in FEV 1 and FVC. In addition, a decrease in breathing frequency was observed, suggesting a reduction in dynamic hyperinflation.

8 March 2024 in The Ultrasound Journal
Verified
Journal Article
Open access
PDF file
Mauro Ariel Castro SayatMauro Ariel Castro Sayat
Mauro Ariel Castro Sayat
Nicolás Colaianni-AlfonsoNicolás Colaianni-Alfonso
Nicolás Colaianni-Alfonso
LVLuigi Vetrugno
Luigi Vetrugno
GOGustavo Olaizola
Gustavo Olaizola
CBCristian Benay
Cristian Benay
CSCatalina Siroti
Catalina Siroti
Background: Lung ultrasound has demonstrated its usefulness in several respiratory diseases management. One derived score, the Lung Ultrasound (LUS) score, is considered a good outcome predictor in patients with Acute Respiratory Failure (ARF). Nevertheless, it has not been tested in patients undergoing non-invasive respiratory support (NIRS). Taking this into account, the aim of this study is to evaluate LUS score as a predictor of 90-day mortality, ETI (Endotracheal intubation) and HFNC (High Flow Nasal Cannula) failure in patients with ARF due to COVID-19 admitted to a Respiratory Intermediate Care Unit (RICU) for NIRS management. Results: One hundred one patients were admitted to the RICU during the study period. Among these 76% were males and the median age was 55 (45–64) years. Initial ARF management started with HFNC, the next step was the use of Continuous Positive Airway Pressure (CPAP) devices and the last intervention was ETI and Intensive Care Unit (ICU) admission. Of the total study population, CPAP was required in 40%, ETI in 26%, while 15% died. By means of a ROC analysis, a LUS ≥ 25 points was identified as the cut-off point for mortality(AUC 0.81, OR 1.40, 95% CI 1.14 to 1.71; p < 0.001), ETI (AUC 0.83, OR 1.43, 95% CI 1.20 to 1.70; p < 0.001) and HFNC failure (AUC 0.75, OR 1.25, 95% CI 1.12 to 1.41; p < 0.001). Kaplan-Meier survival curves also identified LUS ≥ 25 as a predictor of 90-days mortality (HR 4.16, 95% CI 1.27–13.6) and 30 days ETI as well. Conclusion: In our study, a ≥ 25 point cut-off of the Lung Ultrasound Score was identified as a good outcome prediction factor for 90-days mortality, ETI and HFNC failure in a COVID-19 ARF patients cohort treated in a RICU. Considering that LUS score is easy to calculate, a multicenter study to confirm our findings should be performed.

24 June 2024 in Journal of Anesthesia, Analgesia and Critical Care
Verified
Journal Article
Open access
PDF file
Nicolás Colaianni-AlfonsoNicolás Colaianni-Alfonso
Nicolás Colaianni-Alfonso
ICIván Castro
Iván Castro
VCVanesa Cáceres
Vanesa Cáceres
GMGuillermo Montiel
Guillermo Montiel
SMSalvatore Maurizio Maggiore
Salvatore Maurizio Maggiore
LVLuigi Vetrugno
Luigi Vetrugno
Background: Noninvasive ventilation (NIV) is widely employed as the initial treatment for patients with chronic acute exacerbation of obstructive pulmonary disease (AECOPD). Nevertheless, high-flow nasal cannula (HFNC) has been increasingly utilized and investigated to mitigate the issues associated with NIV. Flow rate may play a significant role in diaphragmatic function among subjects recovering from AECOPD. Based on these observations, we conducted a physiological study to assess the impact of HFNC therapy on diaphragmatic function, as measured by US, respiratory rate (RR), gas exchange, and patient comfort at various flow rates. Methods: A prospective physiological pilot study enrolled subjects with a diagnosis of AECOPD who required NIV for more than 24 h. After stabilization, these subjects underwent a 30-min trial using NIV and HFNC at different sequential flow rates (30–60 L/min). At the end of each trial, diaphragmatic displacement (DD, cm) and diaphragmatic thickness fraction (DTF, %) were measured using ultrasound. Additionally, other physiological variables, such as RR, gas exchange, and patient comfort, were recorded. Results: A total of 20 patients were included in the study. DD was no different among trials (p = 0.753). DTF (%) was significantly lower with HFNC-30 L/min compared to HFNC-50 and 60 L/min (p < 0.001 for all comparisons). No significant differences were found in arterial pH and PaCO2 at discontinuation of NIV and at the end of HFNC trials (p > 0.050). During HFNC trials, RR remained unchanged without statistically significant differences (p = 0.611). However, we observed that HFNC improved comfort compared to NIV (p < 0.001 for all comparisons). Interestingly, HFNC at 30 and 40 L/min showed greater comfort during trials. Conclusions: In subjects recovering from AECOPD and receiving HFNC, flows above 40 L/min may not offer additional benefits in terms of comfort and decreased respiratory effort. HFNC could be a suitable alternative to COT during breaks off NIV.

30 July 2024 in Anaesthesia Critical Care & Pain Medicine
Verified
Journal Article
Closed access
Nicolás Colaianni-AlfonsoNicolás Colaianni-Alfonso
Nicolás Colaianni-Alfonso
ATAda Toledo
Ada Toledo
GMGuillermo Montiel
Guillermo Montiel
Mauro Ariel Castro SayatMauro Ariel Castro Sayat
Mauro Ariel Castro Sayat
CCClaudia Crimi
Claudia Crimi
Luigi VetrugnoLuigi Vetrugno
Luigi Vetrugno